Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Guidance tracker
What KIMS guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 11 Nov 2026 | KIMS filed the transcript of its Q2 FY27 earnings conference call held on 5 November 2026 with investors and analysts. Management reported consolidated total revenue of INR1,363 crores (up 41.3% year-on-year, 14% quarter-on-quarter), EBITDA of INR279 crores (EBITDA margin 20.5%) and PAT of INR76 crores. Management... NSE copy | No results filed since | ||
| 08 Aug 2026 | Transcript of KIMS Hospitals' Q1 FY27 earnings conference call held on 4 August 2026, filed on 8 August 2026. Management (Chairman Dr. Bhaskara Rao Bollineni) reported Q1 FY27 total revenue of INR 1,196 crore (up 36.1% year-on-year) and EBITDA of INR 240 crore (up 20.1% year-on-year), with PAT of INR 37 crore.... NSE copy | +11.8 % | +39.9 % | -1.3 % |
| 22 May 2026 | KIMS Hospitals filed the transcript of its Q4 FY26 earnings conference call held on 18 May 2026, hosted by IIFL Capital. Management reported Q4 FY26 total revenue of INR 1,084 crore (up 35.3% YoY) and EBITDA of INR 216 crore (up 6.8% YoY), with EBITDA margin at 19.9%; Q4 PAT was INR 33 crore. For FY26, management... NSE copy | -47.2 % | +35.3 % | -3.0 % |
| 13 Feb 2026 | Filing transmits the transcript of KIMS' Q3 FY26 earnings conference call held on 09 February 2026, hosted by IIFL Capital and uploaded to the company website. Management reported Q3 FY26 consolidated revenue from operations of INR998 crores, up 29.2% year-on-year, and total revenue of INR1,003 crores; EBITDA of... NSE copy | - | - | -5.9 % |
| 14 Nov 2025 | KIMS filed the transcript of its Q2 and H1 FY26 earnings conference call held on 10 November 2025, with the transcript also uploaded to the company website. Management reported Q2 FY26 total revenue of INR 965 crores, up 23.3% year-on-year, with EBITDA of INR 208 crores (down 6.7% year-on-year) and PAT of INR 72... NSE copy | -42.3 % | +29.2 % | +8.7 % |
| 13 Aug 2025 | KIMS filed the transcript of its Q1 FY26 earnings conference call held on 7 August 2025 with investors and analysts. Management reported Q1 FY26 total revenue of INR879 crores (up 26.8% YoY), EBITDA of INR200 crores (up 8.5% YoY) at a 22.7% margin, PAT of INR85 crores and consolidated EPS of INR1.96. Management... NSE copy | -37.5 % | +23.6 % | -3.7 % |
| 17 May 2025 | KIMS filed the transcript of its Q4 FY25 earnings conference call held on 13 May 2025, hosted by IIFL Capital Services. Management reported FY25 total revenue of INR3,067 crores (up 22% YoY) and EBITDA of INR815 crores (up 24.7% YoY), with PAT of INR415 crores against INR336 crores in FY24. Management said Q4 FY25... NSE copy | -9.2 % | +26.6 % | +1.8 % |
| 15 Nov 2024 | Transcript of KIMS Q2 FY25 earnings conference call held on 11 November 2024, filed with the exchanges on 15 November 2024. Management (Bhaskar Rao Bollineni) reported Q2 FY25 gross revenue of INR782 crores (up 19.4% YoY, 12.9% QoQ), EBITDA of INR223 crores (up 23.8% YoY, 21.2% QoQ) and PAT of INR120 crores versus... NSE copy | +28.8 % | +27.5 % | -1.8 % |
Filings tagged as guidance, newest first (8 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 11 Nov 2026 | Legal or regulatory | KIMS filed the transcript of its Q2 FY27 earnings conference call held on 5 November 2026 with investors and analysts. Management reported consolidated total revenue of INR1,363 crores (up 41.3% year-on-year, 14% quarter-on-quarter), EBITDA of INR279 crores (EBITDA margin 20.5%) and PAT of INR76 crores. Management... NSE copy |
| 04 Nov 2026 | Legal or regulatory, Management change | Board of Krishna Institute of Medical Sciences Limited (KIMS) met on 04 November 2026 and approved unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2026, with Limited Review Reports. The Board approved the merger of wholly-owned subsidiary KIMS Hospitals... NSE copy |
| 03 Aug 2026 | Legal or regulatory | Board of Krishna Institute of Medical Sciences approved unaudited standalone and consolidated results for the quarter ended 30 June 2026, with limited review reports from the statutory auditors. Standalone revenue from operations for Q1 FY27 was Rs 4,836 million, against Rs 3,734 million in the corresponding... NSE copy |
| 15 May 2026 | Legal or regulatory, Management change | Board of Krishna Institute of Medical Sciences Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from S.R. Batliboi & Associates LLP (the filing does not state the profit or revenue figures on these pages). Board... NSE copy |
| 15 May 2026 | Management change | Board of Krishna Institute of Medical Sciences Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from S.R. Batliboi & Associates LLP (the page text does not include the reported profit or revenue figures). Board... NSE copy |
| 07 Nov 2025 | Legal or regulatory | Krishna Institute of Medical Sciences Limited's board approved on 07 November 2025 a scheme of amalgamation merging its wholly-owned subsidiaries KIMS Hospitals Private Limited and Chalasani Hospitals Private Limited into the listed company. Turnover as on 31.03.2025 (Rs. in millions): KIMS Hospitals Private... NSE copy |
| 07 Nov 2025 | Legal or regulatory | Board of Krishna Institute of Medical Sciences Limited approved unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2025 on 07 November 2025, with limited review reports. Standalone revenue from operations for the quarter ended 30 September 2025 was Rs 4,300... NSE copy |
| 12 May 2025 | Legal or regulatory, Management change | Board of Krishna Institute of Medical Sciences approved audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with an unmodified audit opinion from S.R. Batliboi & Associates LLP. Board appointed M/s. IKR & Associates as Secretarial Auditors for five years... NSE copy |
| 12 May 2025 | Legal or regulatory, Management change | Board of Krishna Institute of Medical Sciences approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with S.R. Batliboi & Associates LLP's unmodified audit opinion. Board re-appointed Mrs. Y. Prameela Rani as Independent Director for a second term of 5 years,... NSE copy |
| 13 Feb 2025 | Management change | KIMS filed the transcript of its Q3 FY25 earnings conference call with analysts and investors, held on 7 February 2025, and uploaded it to its website. Management (Bhaskara Rao Bollineni) reported Q3 FY25 gross revenue of INR 790 crores, up 29.7% year-on-year and 1% quarter-on-quarter; EBITDA of INR 205 crores, up... NSE copy |
| 15 Nov 2024 | Legal or regulatory, Management change | Transcript of KIMS Q2 FY25 earnings conference call held on 11 November 2024, filed with the exchanges on 15 November 2024. Management (Bhaskar Rao Bollineni) reported Q2 FY25 gross revenue of INR782 crores (up 19.4% YoY, 12.9% QoQ), EBITDA of INR223 crores (up 23.8% YoY, 21.2% QoQ) and PAT of INR120 crores versus... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (11 in all). A list of what was filed, not a judgement of the company.